Autopsy report · NCT03927573

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker

“business decision by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 2 months before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

AvenCell Europe GmbH

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer; Prostate Cancer; Renal Cancer; Transitional Cell Carcinoma

Interventions

GEM3PSCA

Participants

23

Sites

5

Countries

Germany

Trials that died the same way

• A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
  “Sponsor business decision” (97% match in meaning)
• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (96% match in meaning)
• Single Ascending Dose Trial in Patients With Type 2 Diabetes
  “Decision by Sponsor” (91% match in meaning)
• The Effect of a Probiotic Strain on Aspirin-induced GI Damage
  “Decision made by Sponsor” (91% match in meaning)
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
  “Sponsor's strategic business decision” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.